UPDATE 2-Diagnostic company Exact Sciences to buy Genomic Health in $2.8 bln deal [Reuters]
Exact Sciences Corporation (EXAS)
Last exact sciences corporation earnings: 2/11 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.exactsciences.com/investor-relations/default.aspx
Company Research
Source: Reuters
Diagnostic company Exact Sciences to buy Genomic Health in $2.8 billion deal - Reuters 3 Min Read (Reuters) - Exact Sciences Corp ( EXAS.O ) said on Monday it will buy peer Genomic Health Inc ( GHDX.O ) for about $2.8 billion in cash and stock, expanding the cancer diagnostic company’s testing capabilities to breast and prostate cancers. The deal will bring together Exact Sciences’ non-invasive stool screening test for colorectal cancer Cologuard, and Genomic Health’s Oncotype diagnostic tests for various cancers. Genomic Health would help expand Exact Sciences’ focus from screening into treatment selection as well as monitoring, which are highly attractive markets, Canaccord Genuity analyst Mark Massaro said. Under terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in Exact Sciences stock, for a total value of $72 per share. Shares of Genomic Health rose 2.7% to $70.51 in early trading, while Exact Sciences’ shares fell 12.1% to $103.6. Massaro
Show less
Read more
Impact Snapshot
Event Time:
EXAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAS alerts
High impacting Exact Sciences Corporation news events
Weekly update
A roundup of the hottest topics
EXAS
News
- Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax [Yahoo! Finance]Yahoo! Finance
- Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid BiopsyBusiness Wire
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Piper Sandler from $85.00 to $75.00. They now have an "overweight" rating on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target raised by analysts at Jefferies Financial Group Inc. from $84.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Exact Sciences Co. (NASDAQ: EXAS) had its price target lowered by analysts at Citigroup Inc. from $80.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
EXAS
Earnings
- 11/5/24 - Miss
EXAS
Sec Filings
- 11/13/24 - Form SC
- 11/13/24 - Form 4
- 11/8/24 - Form SC
- EXAS's page on the SEC website